Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
7 pending office actions • 3 art units • 4 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Elucid Bioimaging Inc. shows a more active portfolio with 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners and 3 distinct art units, reflecting a broad technological spread. The busiest examiner, VINCENT, DAVID ROBERT, is responsible for 3 pending actions.
The concentration of 3 pending actions with a single examiner out of the total 7 pending office actions suggests that VINCENT, DAVID ROBERT has a significant influence on the portfolio's immediate outcomes. With 4 distinct examiners involved, the company is navigating multiple perspectives within the 3 distinct art units. This distribution requires a strategy that accounts for the different practices of the various examiners and art units involved. Practitioners should note that the 3 distinct art units represent a broad organizational footprint. Managing 7 pending office actions across 4 distinct examiners allows for a robust prosecution presence in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (43%) |
| Double-patenting only | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VINCENT, DAVID ROBERT | 3 | 80.4% | +4.0% |
| SKIBINSKY, ANNA | 2 | 39.0% | +29.1% |
| HARANDI, SIAMAK | 1 | 90.6% | +7.7% |
| AUGER, NOAH ANDREW | 1 | 36.4% | +42.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918308 | STRUCTURED REPRESENTATIONS FOR INTERPRETABLE MACHINE LEARNING APPLICATIONS IN MEDICAL IMAGING | HARANDI, SIAMAK | — |
| 18242413 | SYSTEMS AND METHODS TO AID CLINICAL DECISION SUPPORT FOR ANTI-INFLAMMATORY AND PRO-RESOLVING THERAPIES FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | — |
| 18242386 | SYSTEMS AND METHODS TO AID CLINICAL DECISION SUPPORT FOR GLYCEMIC TREATMENT FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | — |
| 18241718 | CLINICAL DECISION SUPPORT TO AID DYSLIPIDEMIA THERAPIES FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18240190 | SCREENING CANDIDATE DYSLIPIDEMIA AGENTS | AUGER, NOAH ANDREW | 99d overdue |
| 18113944 | IN SILICO MODELING TO SIMULATE CARDIOVASCULAR MEDICAL THERAPY RESPONSE | SKIBINSKY, ANNA | — |
| 17838135 | SYSTEMS AND METHODS FOR PATIENT-SPECIFIC THERAPEUTIC RECOMMENDATIONS FOR CARDIOVASCULAR DISEASE | SKIBINSKY, ANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18240190 | SCREENING CANDIDATE DYSLIPIDEMIA AGENTS | AUGER, NOAH ANDREW | 99d overdue |
| 18113944 | IN SILICO MODELING TO SIMULATE CARDIOVASCULAR MEDICAL THERAPY RESPONSE | SKIBINSKY, ANNA | — |
| 17838135 | SYSTEMS AND METHODS FOR PATIENT-SPECIFIC THERAPEUTIC RECOMMENDATIONS FOR CARDIOVASCULAR DISEASE | SKIBINSKY, ANNA | — |
| Art Unit | Apps |
|---|---|
| 2123 | 1 |
| 1687 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18918308 | STRUCTURED REPRESENTATIONS FOR INTERPRETABLE MACHINE LEARNING APPLICATIONS IN MEDICAL IMAGING | HARANDI, SIAMAK | — | DP | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18242413 | SYSTEMS AND METHODS TO AID CLINICAL DECISION SUPPORT FOR ANTI-INFLAMMATORY AND PRO-RESOLVING THERAPIES FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | — | DP | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18242386 | SYSTEMS AND METHODS TO AID CLINICAL DECISION SUPPORT FOR GLYCEMIC TREATMENT FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | — | DP | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18241718 | CLINICAL DECISION SUPPORT TO AID DYSLIPIDEMIA THERAPIES FOR CARDIOVASCULAR DISEASE | VINCENT, DAVID ROBERT | 2123 | DP | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18240190 | SCREENING CANDIDATE DYSLIPIDEMIA AGENTS | AUGER, NOAH ANDREW | 1687 | §101§103§112DP | Final Rejection | 99d overdue | Pending | Aug 30, 2023 |
| 18113944 | IN SILICO MODELING TO SIMULATE CARDIOVASCULAR MEDICAL THERAPY RESPONSE | SKIBINSKY, ANNA | — | §101§103Other | Non-Final OA | — | Pending | Feb 24, 2023 |
| 17838135 | SYSTEMS AND METHODS FOR PATIENT-SPECIFIC THERAPEUTIC RECOMMENDATIONS FOR CARDIOVASCULAR DISEASE | SKIBINSKY, ANNA | 1635 | §101§103§112 | Non-Final OA | — | Pending | Jun 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial